Home
Conditions
Lymphoma, B-Cell

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

1,618 public trials 340 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Enrolling by Invitation

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

NCT03226704

Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Hematologic Diseases, +15 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Enrolling by Invitation

A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

NCT07348575

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: The Second Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China

View Trial Details

Enrolling by Invitation

Watch and Wait or Worry and Wait in Indolent Lymphoma

NCT07173790

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +32 more
Locations: Samsung Medical Center Seoul, Gangnam-gu, South Korea

Korea UniversityKorea University Guro Hospital Seoul, Guro-gu, South Korea

Seoul National University Hospital Seoul, Jongno-gu, South Korea

The Catholic University of Korea Seoul, Seocho-gu, South Korea

View Trial Details

Enrolling by Invitation

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

NCT06827782

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: 2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China

View Trial Details

Enrolling by Invitation

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

NCT05690191

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Second Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Enrolling by Invitation

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

NCT04491721

Conditions: Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing, China

View Trial Details

Not Yet Recruiting

Study Of KITE-753 in R/R B-Cell ALL

NCT07674823

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: UT MD Anderson Houston, Texas, United States

View Trial Details

Not Yet Recruiting

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

NCT07729397

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Diffuse Large B-Cell Lymphoma (DLBCL), +17 more
Locations: Houston Methodist Hospital Houston, Texas, United States

View Trial Details

Not Yet Recruiting

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

NCT07724457

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +18 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +23 more
Locations: Weill Cornell Medicine/NewYork-Presbyterian Hospital New York, United States

View Trial Details

Lymphoma, B-Cell

Lymphoma, B-Cell trial results

Related conditions